BI-1361849 is under clinical development by Boehringer Ingelheim International and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BI-1361849’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 17 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BI-1361849 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BI-1361849 overview

BI-1361849 (CV-9202) is under development for the treatment of non-small cell lung cancer in combination with radiation therapy and afatinib. It is administered intradermally. It is a RNActive-derived mRNA (messengerRNA) therapeutic comprising of six RNActive-derived molecules coding for 6 different NSCLC associated antigens, MAGE-C1, MAGE-C2, NY-ESO-1, survivin, 5T4 and Muc1. It is developed based on the RNActive technology. It was under development for the treatment of non-small cell lung cancer as a first line therapy.

Boehringer Ingelheim International overview

Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Quick View BI-1361849 LOA Data

Report Segments
  • Innovator
Drug Name
  • BI-1361849
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.